Advanced search
Publication Cover
Future Oncology Volume 20, 2024 - Issue 6
Submit an article Journal homepage
885
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Real-World Treatment Patterns, Survival, Health Resource use and Costs Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma

Mahek Garg1 Merck & Co., Inc., Rahway, NJ07065, USAORCID Iconhttps://orcid.org/0000-0003-2479-555X
ORCID Icon,
Justin Puckett2 COVIA Health Solutions, Lansdale, PA19446, USAORCID Iconhttps://orcid.org/0000-0002-5135-7216
ORCID Icon,
Sachin Kamal-Bahl2 COVIA Health Solutions, Lansdale, PA19446, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7559-3216
ORCID Icon,
Monika Raut1 Merck & Co., Inc., Rahway, NJ07065, USAORCID Iconhttps://orcid.org/0009-0000-9538-2934
ORCID Icon,
Katherine Elizabeth Ryland1 Merck & Co., Inc., Rahway, NJ07065, USAORCID Iconhttps://orcid.org/0009-0001-1749-7880
ORCID Icon,
Jalpa A Doshi3 Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA19104, USAORCID Iconhttps://orcid.org/0000-0002-3263-4337
ORCID Icon &
Scott F Huntington4 Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT06510, USAORCID Iconhttps://orcid.org/0000-0001-7071-6475
ORCID Icon show all
Pages 317-328 | Received 08 Mar 2023, Accepted 26 Oct 2023, Published online: 05 Dec 2023

References

  • Thandra KC , BarsoukA, SaginalaK, PadalaSA, BarsoukA, RawlaP. Epidemiology of Non-Hodgkin’s Lymphoma. Med. Sci.9(1), 5 (2021).
  • Coiffier B , ThieblemontC, VanDen Neste Eet al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood116(12), 2040–2045 (2010).
  • Friedberg JW . Relapsed/refractory diffuse large B-cell lymphoma. Hematol. Am. Soc. Hematol. Educ. Program.2011, 498–505 (2011).
  • Coiffier B , SarkozyC. Diffuse large B-cell lymphoma: r-CHOP failure-what to do?Hematol. Am. Soc. Hematol. Educ. Program.2016(1), 366–378 (2016).
  • Danese MD , GriffithsRI, GleesonMLet al. Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy. Leuk. Lymphoma58(5), 1094–1104 (2017).
  • Huntington S , KeshishianA, McGuireM, XieL, BaserO. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients. Leuk. Lymphoma59(12), 2880–2887 (2018).
  • Shaw J , HarveyC, RichardsC, KimC. Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database. Leuk. Lymphoma60(13), 3235–3243 (2019).
  • Smith A , HowellD, PatmoreR, JackA, RomanE. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br. J. Cancer105(11), 1684–1692 (2011).
  • Delarue R , TillyH, MounierNet al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol.14(6), 525–533 (2013).
  • Wieringa A , BoslooperK, HoogendoornMet al. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br. J. Haematol.165(4), 489–496 (2014).
  • Chronic Conditions Data Warehouse . Centers for Medicare and Medicaid Services (2023). www2.ccwdata.org
  • Morrison VA , BellJA, HamiltonLet al. Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA. Future Oncol. Lond. Engl.14(25), 2627–2642 (2018).
  • Yang X , LalibertéF, GermainGet al. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the US The Oncologist. 26(5), e817–e826 (2021).
  • Squires P , PuckettJ, RylandKEet al. Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs. Leuk. Lymphoma64(11), 1752–1770 (2023).
  • SAS Institute . SAS: Analytics, Artificial Intelligence and Data Management | SAS. www.sas.com/en_us/home.html
  • Purdum A , TieuR, ReddySR, BroderMS. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies. The Oncologist.24(9), 1229–1236 (2019).
  • Ren J , AscheCV, ShouY, GalaznikA. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA. J. Comp. Eff. Res.8(6), 393–402 (2019).
  • Tkacz J , GarciaJ, GitlinMet al. The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy. Leuk. Lymphoma61(7), 1601–1609 (2020).
  • Di M , HuntingtonSF, OlszewskiAJ. Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients. The Oncologist.26(2), 120–132 (2021).
  • Jantunen E , CanalsC, RambaldiAet al. Autologous stem cell transplantation in elderly patients (> or = 60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica93(12), 1837–1842 (2008).
  • Andorsky DJ , CohenM, NaeimA, Pinter-BrownL. Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over. Bone Marrow Transplant.46(9), 1219–1225 (2011).
  • Huntington SF , HoagJR, ZhuWet al. Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma. Cancer124(21), 4211–4220 (2018).
  • Freed M . Seven in Ten Medicare Beneficiaries Did Not Compare Plans During Past Open Enrollment Period.KFF (2021). www.kff.org/medicare/issue-brief/seven-in-ten-medicare-beneficiaries-did-not-compare-plans-during-past-open-enrollment-period/

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.